Pfm Health Sciences, LP Jounce Therapeutics, Inc. Transaction History

Pfm Health Sciences, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.64 - $1.99 $2.4 Million - $7.46 Million	-3,748,562 Reduced 91.55%	345,926 $383,000
Q3 2022 Nov 14, 2022	BUY	$2.73 - $4.92 $395,358 - $712,514	144,820 Added 3.67%	4,094,488 $9.58 Million
Q2 2022 Aug 15, 2022	SELL	$2.8 - $7.67 $64,959 - $177,944	-23,200 Reduced 0.58%	3,949,668 $12 Million
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $881,967 - $1.2 Million	124,046 Added 3.22%	3,972,868 $33.2 Million
Q3 2021 Nov 15, 2021	BUY	$5.04 - $8.73 $2.95 Million - $5.12 Million	585,989 Added 17.96%	3,848,822 $28.6 Million
Q1 2021 May 17, 2021	BUY	$6.73 - $13.87 $22 Million - $45.3 Million	3,262,833 New	3,262,833 $33.5 Million
Q2 2018 Aug 14, 2018	SELL	$7.27 - $21.88 $14 Million - $42.1 Million	-1,923,651 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$13.4 - $28.4 $2.19 Million - $4.65 Million	-163,573 Reduced 7.84%	1,923,651 $43 Million
Q4 2017 Feb 14, 2018	BUY	$12.52 - $17.82 $4.5 Million - $6.4 Million	359,227 Added 20.79%	2,087,224 $26.6 Million
Q3 2017 Nov 14, 2017	BUY	$11.17 - $16.99 $19.3 Million - $29.4 Million	1,727,997	1,727,997 $26.9 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

Stay updated on Pfm Health Sciences, LP with notifications on news.